SCHEMBL1692246

SCHEMBL1692246

C[C@@]1(c2ccccc2)CCCCCO1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 3/20 0.41
SLC6A2 P23975 2/20 0.41
SLC6A3 Q01959 2/20 0.41
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
CYP2B6 P20813 1/20 0.39
PRCP P42785 1/20 0.39
GRIN1 Q05586 1/20 0.39
KCNH2 Q12809 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39
GRIN2C Q14957 1/20 0.39
GRIN3A Q8TCU5 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
HSD11B1 P28845 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11465523 0.98 HSD11B1 (0.39) SLC6A4SLC6A2SLC6A3HSD11B1OPRM1
SCHEMBL9608820 0.92 HSD11B1 (0.40) HSD11B1OPRM1CYP1A2
SCHEMBL16990752 0.79 HSD11B1 (0.42) SLC6A4SLC6A2SLC6A3HSD11B1OPRM1
SCHEMBL9101366 0.78 HCAR3 (0.37)
SCHEMBL21961580 0.77 SLC6A4 (0.45) SLC6A4SLC6A2SLC6A3GRIN1GRIN2A
SCHEMBL7003423 0.76 SLC6A2 (0.41) SLC6A4SLC6A2SLC6A3GRIN2DGRIN3B
SCHEMBL5616835 0.75 CYP1A2 (0.42) SLC6A2SLC6A3SIGMAR1OPRM1CYP1A2
SCHEMBL1279335 0.74 OPRM1 (0.50) SLC6A4SLC6A2SLC6A3HSD11B1OPRM1
SCHEMBL8666950 0.74 DPP4 (0.41) SLC6A4SLC6A2SLC6A3GRIN2DGRIN3B
SCHEMBL28770898 0.73 DPP4 (0.37) SLC6A4SLC6A2SLC6A3OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722662-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-05-13 US disclosed
US-20130267494-A1 1,4-OXAZEPANE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-10-10 US disclosed
US-20120088748-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130267494-A1 1,4-OXAZEPANE DERIVATIVES MAOB, SLC6A4, SLC6A2 SLC6A4 2/4885SLC6A2 3/4885SLC6A3 6/4885
US-20120088748-A1 HETEROCYCLIC COMPOUNDS SLC6A2, MAOB, MAOA SLC6A4 5/4885SLC6A2 1/4885SLC6A3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.